RecruitingOBSERVATIONAL

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

This study is investigating a medicine called maribavir. It's for adults who have severe kidney disease or kidney failure, including those on dialysis, and have developed a Cytomegalovirus (CMV) infection after receiving an organ transplant. Rather than conducting new tests or giving new treatments, this study will carefully look at information that's already in patients' medical records. The goal is to understand how safe maribavir has been for these patients in real-world situations. Importantly, taking part in this study won't change your medical care or treatment in any way, as it only involves reviewing data that has already been collected as part of your routine healthcare.

At a glance

Status

Recruiting

Sponsor

Takeda

Enrolment target

Start

03 Nov 2025

Estimated completion

31 Jan 2027

Cytomegalovirus (CMV)Kidney Disease Kidney Failure

What is this study about?

This study is focused on a medicine called maribavir. It's being used for adults who have had an organ transplant, like a kidney transplant, and have since developed a common virus called Cytomegalovirus, or CMV. This virus can be more serious in people with weakened immune systems, such as after an organ transplant.

Specifically, the study is looking at adults who also have serious kidney problems – either severe kidney disease or complete kidney failure. This includes people who might be receiving treatments like dialysis to help their kidneys work.

The main purpose of this study is to understand how safe maribavir is for these patients. Instead of doing new medical tests or asking people to take new medicines, the researchers will be reviewing existing medical information from patient records. This means your doctors will continue to give you the best care for your conditions, and your involvement in this study won't change your treatment plan at all.

Key takeaways

This study is about the safety of maribavir for CMV after transplant.
It focuses on adults with severe kidney problems or kidney failure.
Researchers will only look at existing medical records, not change your care.
There are no extra appointments, tests, or medicines for participants.
Insights from this study could help improve future treatments for others.

Who may be eligible?

To be included in this study, you would need to be an adult, aged 18 or older.

You also need to have severe kidney disease or kidney failure. This means your kidneys aren't working as well as they should, which might be measured by a specific blood test. You may also be on dialysis. On top of this, you must have had an organ transplant, such as a kidney or bone marrow transplant.

Finally, you would have been diagnosed with a CMV infection after your transplant that was hard to treat, and you would have already started taking the medicine maribavir as part of your regular medical care.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have severe kidney disease or kidney failure (e.g., on dialysis)?
Have you had an organ transplant (like a kidney or bone marrow transplant)?
Did you have a CMV infection after your transplant that was hard to treat?
Have you already received at least one dose of the medicine maribavir as part of your normal care?

Answer every question to see your result.

What does participation involve?

Taking part in this study is very straightforward, as it doesn't involve any changes to your current medical care. You won't need to attend any extra appointments, take any new medications, or undergo any additional tests. The study simply involves looking at information that's already in your medical notes and records, which has been collected as part of your usual visits and treatments. This means your regular doctors will continue to manage your health as usual, and you won't have any extra tasks or follow-up appointments directly related to this study. Your participation simply allows researchers to learn from your existing health information.

Potential risks and benefits

Since this study only involves reviewing existing medical records, there are no direct medical risks or benefits to you. Your medical care will not change because of this study. The potential benefit is that the information gathered could help doctors better understand the safety of maribavir for people like you, which may improve future treatments for others. You always have the right to withdraw your permission for your data to be used, if consent was required for data collection.

Locations (25)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Hopital Erasme - PPDS
Verified postcode
Anderlecht, Belgium· Not yet recruiting
UZ Leuven - PPDS
Verified postcode
Leuven, Belgium· Not yet recruiting
North Estonia Medical Centre Foundation
Verified postcode
Tallinn, Estonia· Recruiting
Tartu University Hospital
Verified postcode
Tartu, Estonia· Recruiting
CHU de Brest - Hopital La Cavale Blanche
Verified postcode
Brest, France· Recruiting
CHU de Bordeaux - Hopital Pellegrin
Verified postcode
Bordeaux, France· Recruiting
CHU de Montpellier - Hopital Lapeyronie
Verified postcode
Montpellier, France· Recruiting
CHU de Grenoble Alpes - Hopital Michallon
Verified postcode
La Tronche, France· Recruiting
AP-HP - Hopital Henri Mondor
Verified postcode
Créteil, France· Recruiting
Universitatsklinikum Wurzburg
Verified postcode
Würzburg, Germany· Not yet recruiting
Universitatsklinikum Leipzig
Verified postcode
Leipzig, Germany· Not yet recruiting
Azienda Ospedaliera Dei Colli - Ospedale Monaldi
Verified postcode
Naples, Italy· Not yet recruiting

Common questions

What is CMV?

CMV stands for Cytomegalovirus. It's a common virus that most people carry, but it can cause problems, especially in people with weakened immune systems, like after an organ transplant.

What is maribavir?

Maribavir is a medicine used to treat CMV infections that are difficult to get rid of, especially after an organ transplant.

Will taking part in this study change my treatment?

No, this study will not change your medical care or treatment in any way. It only involves looking at information already in your medical records.

Do I need to do anything extra if I'm in this study?

No, you don't need to do anything extra. There are no additional visits, tests, or medications involved for you.

How will my personal information be handled?

The study will only review data collected as part of your normal clinical care, and this information will be handled carefully to protect your privacy.

How to find out more

Takeda Contact

medinfous@takeda.com +1-877-825-3327 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.